Is It Time To Reassess Haemonetics (HAE) After The Recent Share Price Jump
- Wondering whether Haemonetics stock at around US$65.49 is starting to look attractive, or if the recent activity is masking valuation risks you should not ignore?
- The share price has moved sharply in the short term, with a 16.3% gain over the last 7 days and a 9.3% gain over the last 30 days, even though the year to date return is still down 18.1% and the 1 year return is down 0.9%.
- These moves sit against a longer 3 year period where the stock is down 21.3%, while the 5 year return is up 16.0%. This gives useful context when thinking about what is driving sentiment now. For investors, the mix of recent strength and mixed longer term results raises a clear question around whether the current price properly reflects the underlying…
Source link
